Anthropic PBC is expanding its artificial intelligence capabilities into scientific research with the launch of Claude Science, a platform engineered to ease the workload of researchers grappling with repetitive analytical tasks. Unveiled on June 30, the tool marks another significant step in the San Francisco-based company's strategy to embed its AI systems across professional sectors, following similar pushes into legal services and financial analysis. The software becomes available in beta to Anthropic's subscription-paying users, positioning the company at the intersection of cutting-edge artificial intelligence and the global research enterprise.
Claude Science consolidates access to more than 60 scientific databases and analytical tools that researchers typically navigate separately, creating a unified interface for automating multistep workflows. Scientists can now pose questions in plain language rather than constructing complex database queries, receiving synthesised answers drawn from integrated sources. The platform's capabilities span protein structure prediction and other computationally intensive biology and chemistry operations, addressing pain points that consume significant researcher time. This integration approach reflects a broader industry trend toward consolidating fragmented digital ecosystems into cohesive, AI-powered platforms that reduce friction in professional workflows.
The timing of Claude Science's release carries particular significance given the company's commercial trajectory and strategic positioning. Anthropic, currently valued at US$965 billion (RM3.94 trillion), is preparing for a potential initial public offering as early as autumn, making moves into high-value professional sectors crucial for justifying its valuation to public markets. The company's simultaneous announcement that it is initiating in-house preclinical drug discovery programmes underscores its commitment to demonstrating tangible applications beyond software provision. By targeting disease areas that traditional pharmaceutical and biotech companies consider commercially unattractive, Anthropic positions itself as both a technology provider and a biomedical innovator.
Eric Kauderer-Abrams, heading Anthropic's life sciences division, outlined this dual strategy during the June 30 announcement. The firm intends to pursue research in disease categories that fall outside conventional industry focus, potentially addressing therapeutic gaps in orphan diseases and other neglected conditions. This approach theoretically combines Anthropic's AI capabilities with the flexibility to pursue scientifically promising but commercially challenging research pathways. For Malaysian and Southeast Asian readers, this development signals the deepening integration of AI into global drug discovery pipelines—a process that could eventually influence pharmaceutical availability and pricing in the region.
Anthropicís commercial aggressiveness in automating professional services has generated market anxiety and regulatory scrutiny. In February, the company introduced Claude Cowork, a tool capable of automating legal tasks including contract review and document analysis. That announcement reportedly contributed to a US$1 trillion (RM4.08 trillion) stock market downturn, as investors grappled with concerns about technological displacement of professional workers and service provider obsolescence. The market's nervousness reflects genuine uncertainty about which professional services remain defensible against AI automation and which sectors face fundamental disruption. Claude Science's emergence into research automation may trigger similar apprehension among scientific services providers and analytical firms dependent on traditional research workflows.
The announcement event in San Francisco featured endorsements from pharmaceutical industry heavyweights, lending credibility to Anthropic's claims about practical applicability. Vas Narasimhan, chief executive of Novartis AG and an Anthropic board member, joined Anthropic CEO Dario Amodei in acknowledging that bold proclamations must now translate into measurable patient benefits. Narasimhan emphasised the necessity of concrete results, reflecting pharmaceutical industry scepticism toward technology firms making sweeping claims about drug discovery acceleration. His presence alongside Chris Boerner, CEO of Bristol-Myers Squibb Co, suggested that major pharmaceutical entities view Claude Science as worthy of serious evaluation rather than dismissal as speculative technology.
Narasimhan also articulated concerns about regulatory frameworks, cautioning that premature crises should not drive AI governance decisions. His comment that "it would be a shame that a crisis is what pushes us to get appropriate AI regulation in place" reflects growing recognition within industry leadership that proactive regulation may prevent disruptive incidents. For Malaysian policymakers and regulators monitoring AI development, this statement from a prominent international pharmaceutical executive carries weight—it suggests that multinational corporations increasingly expect regulatory structures to evolve before major incidents force reactive policy-making.
Claude Science operates on existing Claude models, particularly the Opus 4.8 version released in May, rather than introducing entirely new underlying architecture. This choice indicates Anthropic's confidence in current model capabilities while suggesting that integration and interface design represent the primary innovation vectors. The platform incorporates transparency mechanisms allowing scientists to verify information accuracy and understand how generated images and analyses were produced. This emphasis on traceability addresses legitimate scientific concerns about reproducibility and methodological clarity—issues that have plagued previous AI applications in research contexts where "black box" decision-making proves incompatible with scientific rigor.
The Claude Science rollout occurs against the backdrop of significant regulatory constraints imposed on Anthropic's most advanced models. The company recently disabled access to its Fable 5 and Mythos 5 models pursuant to a Trump administration directive restricting foreign national access to advanced AI technology. On June 26, Anthropic secured approval to partially restore Mythos 5 access after addressing national security concerns, though Fable 5 restrictions remain in place. These restrictions exemplify the geopolitical dimension of AI governance, where advanced models become treated as technology subject to export controls comparable to defence-sensitive materials. For Southeast Asian researchers and institutions relying on cutting-edge AI tools, such restrictions create asymmetric access to technological capabilities, potentially widening research and innovation gaps between countries with established bilateral AI technology arrangements and those without such frameworks.
Anthropicís strategic push toward demonstrable applications in research and drug discovery reflects broader industry recognition that AI adoption requires tangible value demonstration beyond abstract capability metrics. The company's emphasis on automation, integration, and transparency represents a deliberate positioning strategy targeting professional sectors where measurable productivity gains can justify substantial licensing costs. Over the coming year, Amodei indicated that Anthropic intends to showcase concrete successes in identifying novel drug targets through AI-assisted discovery. These outcomes will determine whether Claude Science becomes a genuinely transformative research tool or remains a sophisticated but ultimately incremental advancement in scientific computing.
The broader implications extend across Southeast Asia's emerging biotech and research sectors. As advanced AI tools become integrated into global drug discovery and scientific research workflows, regional institutions must develop capacity to utilise these platforms effectively while maintaining critical evaluation of their capabilities and limitations. The experience of scientific institutions in Malaysia, Singapore, and throughout the region with Claude Science and similar tools will shape technology adoption patterns and influence positioning within emerging global AI-driven research ecosystems. Simultaneously, the geopolitical constraints affecting AI model access underscore the strategic importance of developing regional AI capabilities rather than remaining entirely dependent on foreign technology platforms.
